• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up1.03% Nasdaq Up1.29%

    More On CIR.AX



    News & Info


    Analyst Coverage


    • Major Holders
    • Insider Transactions
    • Insider Roster


    Circadian Technologies Limited (CIR.AX)

    0.16 0.00(0.00%) 8:33PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    Circadian Technologies Limited
    650 Chapel Street
    Suite 0403
    South Yarra, VIC 3141
    Australia - Map
    Phone: 61 3 9826 0399
    Fax: 61 3 9824 0083
    Website: http://www.circadian.com.au

    Index Membership:N/A
    Industry:Drug Manufacturers - Major
    Full Time Employees:N/A

    Business Summary 

    Circadian Technologies Limited develops and commercializes therapies for eye and cancer diseases in Australia. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) C and D, and R3 targets, which are used for the treatment of diseases associated with angiogenesis. The company’s lead molecule includes OPT-302, a soluble form of VEGFR-3 that is used for the treatment of neovascular age-related macular degeneration and dry-eye diseases. Its product pipeline also comprises VGX-100, a monoclonal antibody for VEGF-C that has completed Phase IA/IB clinical study in advanced cancer patients; and IMC-3C5, an antibody targeting VEGFR-3. In addition, the company develops CUPGUIDE, a diagnostic test, which is used in the treatment of cancers of unknown primary; and VEGF-D LAM Diagnostic, an ELISA-based diagnostic test to measure circulating levels of VEGF-D, as well as offers VEGF-C/VEGF-D reagents under the Vegenics brand name. Further, it develops novel forms of insulin through DiMiTech Platform that is used for the treatment of diabetes. Circadian Technologies Limited is based in South Yarra, Australia.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Circadian Technologies Limited

    Key Executives 
    Ms. Dominique Gayle Fisher BA (Hons), MAICD, 58
    Chairman, Chairman of Remuneration Committee and Member of Audit & Risk Committee
    Ms. Megan Baldwin Ph.D.,
    Chief Exec. Officer, Managing Director and Director
    Mr. Michael Tonroe ,
    Chief Financial Officer and Company Sec.
    Mr. Richard Chadwick Ph.D.,
    Head of Intellectual Property
    Mr. Michael Gerometta Ph.D.,
    Head of CMC Devel.
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in AUD.